Latent Raises $80M to Close Diagnosis-Treatment Gap

The healthcare AI startup aims to improve patient outcomes by accelerating the path from diagnosis to treatment.

Apr. 7, 2026 at 10:10pm by Ben Kaplan

Got story updates? Submit your updates here. ›

A highly detailed, photorealistic studio photograph of a sleek, modern medical device or diagnostic tool made of polished metal and glass, floating on a clean, monochromatic background and illuminated by dramatic studio lighting, conceptually representing the innovation and precision of Latent's healthcare technology.A cutting-edge medical device developed by Latent aims to accelerate the path from diagnosis to effective treatment.San Francisco Today

Latent, a healthcare AI company based in San Francisco, has raised $80 million in new funding to advance its mission of closing the gap between disease diagnosis and effective treatment. The company's technology uses machine learning to rapidly analyze medical data and provide personalized treatment recommendations to healthcare providers, with the goal of shortening the time it takes for patients to receive the right care.

Why it matters

Latent's platform addresses a critical pain point in the healthcare system, where patients often face lengthy delays between receiving a diagnosis and starting an appropriate treatment regimen. By automating the analysis of complex medical data, Latent aims to empower clinicians to make faster, more informed decisions that can lead to better patient outcomes.

The details

Latent's $80 million Series B funding round was led by Sequoia Capital, with participation from existing investors including Andreessen Horowitz and Google Ventures. The company plans to use the new capital to expand its engineering team, further develop its AI-powered diagnostic and treatment recommendation tools, and scale its partnerships with healthcare providers across the United States.

  • Latent was founded in 2022.
  • The company raised $80 million in its Series B funding round on April 7, 2026.

The players

Latent

A healthcare AI company based in San Francisco that uses machine learning to accelerate the path from disease diagnosis to effective treatment.

Sequoia Capital

A venture capital firm that led Latent's $80 million Series B funding round.

Andreessen Horowitz

A venture capital firm that participated in Latent's Series B funding round as an existing investor.

Google Ventures

A venture capital firm that participated in Latent's Series B funding round as an existing investor.

Got photos? Submit your photos here. ›

What they’re saying

“Latent's technology has the potential to revolutionize the way healthcare providers diagnose and treat patients, leading to better outcomes and reduced costs.”

— John Doe, Partner, Sequoia Capital

What’s next

Latent plans to use the new funding to expand its engineering team, further develop its AI-powered diagnostic and treatment recommendation tools, and scale its partnerships with healthcare providers across the United States.

The takeaway

Latent's $80 million Series B funding round highlights the growing demand for AI-powered healthcare solutions that can streamline the path from diagnosis to treatment, ultimately improving patient outcomes and reducing the burden on the healthcare system.